The pattern of interleukin-1β (IL-1β) and its modulating agents IL-1 receptor antagonist and IL-1 soluble receptor type II in acute meningococcal infections

Blood

Volumn 90, Issue 3, 1997, Pages 1101-1108

  Van Deuren, Marcel ^a   Van Der Ven Jongekrijg, Johanna ^b   Vannier, Edouard ^b   Van Dalen, Roelof ^b   Pesman, Gerard ^b   Bartelink, Anton K M ^b   Dinarello, Charles A ^b   Van Der Meer, Jos W M ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; ENDOTOXIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; ANTIINFLAMMATORY AGENT; IL1RN PROTEIN, HUMAN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR TYPE II; SIALOGLYCOPROTEIN;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL MENINGITIS; CEREBROSPINAL FLUID ANALYSIS; CHILD; CONTROLLED STUDY; ENDOTOXEMIA; FEMALE; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INFANT; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEPTIC SHOCK; ACUTE DISEASE; BIOSYNTHESIS; BLOOD; CEREBROSPINAL FLUID; COMPARATIVE STUDY; DRUG EFFECT; EPIDEMIC MENINGITIS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; CHILD; CHILD, PRESCHOOL; DEXAMETHASONE; ENDOTOXINS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFANT; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MALE; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL INFECTIONS; MIDDLE AGED; RECEPTORS, INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-1 TYPE II; SHOCK, SEPTIC; SIALOGLYCOPROTEINS;

EID: 0030611646     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.3.1101     Document Type: Article

References (50)

1. Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T: The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin-6, interleukin-1. and fatal outcome. J Exp Med 169:333, 1989
2. Brandtzaeg P, Kierulf P, Gaustad P, Skulberg A, Bruun JN, Halvorsen S, Sørensen E: Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 159:195, 1989
3. Waage A, Halstensen A, Espevik T: Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet I:355, 1987
4. Girardin E, Grau GE, Dayer J-M, Roux-Lombard P, J5 Study Group, Lambert P-H: Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 319:397, 1988
5. Halstensen A, Ceska M, Brandtzaeg P, Redl H, Naess A, Waage A: Interleukin-8 in serum and cerebrospinal fluid from patients with meningococcal disease, J Infect Dis 167:471, 1993
6. Brandtzaeg P, Halstensen A, Kierulf P, Espevik T, Waage A: Molecular mechanisms in the compartmentalized inflammatory response presenting as meningococcal meningitis or septic shock. Microb Path 13:423, 1992
7. Waage A, Halstensen A, Espevik T, Brandtzaeg P: Compartmentalization of TNF and IL-6 in meningitis and septic shock. Med Inflam 2:23, 1993
8. Waage A, Halstensen A, Espevik T, Brandtzæg P: Cytokines in meningococcal disease. Baillieres Clin Infect Dis 1:97, 1994
9. Van Deuren M, Van der Ven-Jongekrijg J, Demacker PNM, Bartelink AKM, Van Dalen R, Sauerwein RW, Gallati H, Vannice JL, Van der Meer JWM: Differential expression of proinflammatory cytokines and their inhibitors during the course of meningococcal infections. J Infect Dis 169:157, 1994
10. Derkx HHF, Marchant A, Goldman M, Bijlmer RPGM, Van Deventer SJH: High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock. J Infect Dis 171:229, 1995
11. Lehmann AK, Halstensen A, Sørnes S, Røkke O, Waage A: High levels of interleukin-10 in serum are associated with fatality in meningococcal disease. Infect Immun 63:2109, 1995
12. Van Deuren M, Van der Ven-Jongekrijg J, Bartelink AKM, Van Dalen R, Sauerwein RW, Van der Meer JWM: Correlation between proinflammatory cytokines and antiinflammatory mediators and the severity of disease in meningococcal infections. J Infect Dis 172:433, 1995
13. Girardin E, Roux-Lombard P, Grau GE, Suter P, Gallati H, The J5 Study Group, Dayer J-M: Imbalance between tumor necrosis factor-α and soluble TNF receptor concentrations in severe meningococcaemia. Immunology 76:20, 1992
14. Frieling JTM, Van Deuren M, Wijdenes J, Van Dalen R, Bartelink AKM, Van der Linden CJ, Sauerwein RW: Patterns of interleukin-6 and its soluble receptor during acute meningococcal infections and the effect of plasma or whole blood exchange. Crit Care Med 24:1801, 1996
15. Arend WP: Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest 88:1445, 1991
16. Symons JA, Eastgate JA, Duff GW: Purification and characterization of a novel soluble receptor for interleukin 1. J Exp Med 174:1251, 1991
17. Sims JE, Dower SK: Interleukin-1 receptors. Eur Cytokine Netw 5:539, 1994
18. Sims JE, Gayle MA, Slack JL, Alderson MR, Bird TA. Giri JG, Collotta F, Re F, Mantovani A, Shanebeck K, Grabstein KH, Dower SK: Interleukin 1 signaling occurs exclusively via the type I receptor. Proc Natl Acad Sci USA 90:6155, 1993
19. Colotta F, Re F, Muzio M, Bertini R, Polentarutti N, Sironi M, Giri JG, Dower SK, Sims JE, Mantovani A: Interleukin-1 type II receptor: A decoy target for IL-1 that is regulated by IL-4. Science 261:472, 1993
20. Re F, Muzio M, De Rossi M, Polentarutti N, Giri JG, Mantovani A, Colotta F: The type II "receptor" as a decoy target for interleukin-1 in polymorphonuclear leukocytes: Characterization of induction by dexamethasone and ligand binding properties of the released decoy receptor. J Exp Med 179: 739, 1994
21. Svenson M, Bagge Hansen M, Heegaard P, Abell K, Bendtzen K: Specific binding of interleukin 1 (IL-1β) and IL-1 receptor antagonist (IL-1ra) to human serum. High affinity of IL-1ra to soluble IL-1 receptor type I. Cytokine 5:427, 1993
22. Arend WP, Malyak M, Smith MF, Whisenand TD, Slack JL, Sims JE, Giri JG, Dower SK: Binding of IL-1α, IL-1β and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J Immunol 153:4766, 1994
23. Symons JA, Young PR, Duff GW: Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1β precursor and loses affinity for IL-1 receptor antagonist. Immunology 92:1714, 1995
24. Burger D, Chicheportiche R, Giri JG, Dayer J-M: The inhibi-tory action of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 receptor. J Clin Invest 96: 38, 1995
25. Fanslow WC. Sims JE, Sassenfeld H, Morrissey PJ, Gillis S, Dower SK, Widmer MB: Regulation of alloreactivity in vivo by a soluble form of the interleukin-1 receptor. Science 248:739, 1990
26. Giri JG, Wells J, Dower SK, McCall CE, Guzman RN, Slack J, Bird TA, Shanebeck K, Grabstein KH, Sims JE, Alderson MR: Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor regulation in IL-1 responses. J Immunol 153:5802, 1994
27. Halstensen A, Pedersen SHJ, Haneberg B, Bjorvatn B, Solberg CO: Case fatality of meningococcal disease in western Norway. Scand J Infect Dis 19:35, 1987
28. Sinclair JF, Skeoch CH, Hallworth D: Prognosis of meningococcal septicaemia. Lancet 2:38, 1987
29. Thomson APJ, Sills JA, Hart CA: Validation of the Glasgow meningococcal septicemia prognostic score: A 10-year retrospective survey. Crit Care Med 19:26, 1991
30. Van Deuren M, Santman FW, Van Dalen R. Sauerwein RW, Span LFR, Van der Meer JWM: Plasma exchange and whole blood exchange in meningococcal sepsis. Clin Infect Dis 15:424, 1992
31. Drenth JPH, Van Uum SHM, Van Deuren M, Pesman GJ, Van der Ven-Jongekrijg J, Van der Meer JWM: Endurance run increases circulating IL-6 and IL-1ra but down regulates ex vivo TNF-α and IL-1β production. J Appl Physiol) 79:1497, 1995
32. Halstensen A, Ceska M, Brandtzaeg P, Redl H, Naess A, Waage A: Interleukin-8 in serum and cerebrospinal fluid from patients with meningococcal disease. J Infect Dis 167:471, 1993
33. Van Deuren M, Van der Ven-Jongekrijg J, Kraak W, Sauerwein RW, Van der Meer JWM: Cytokine pattern during acute phase and recovery of meningococcal infections; high levels of immunoreactive IL-1β. during recovery (Abstract). Eur Cytokine Netw 3:215, 1992
34. Lisi PJ, Chu CW, Koch GA, Endres S, Lonnemann G, Dinarello CA: Development and use of radio immunoassay for human interleukin-1β. Lymphokine Res 6:229, 1987
35. Cannon JG, Nerad JL, Poutsiaka DD, Dinarello CA: Measuring cytokines. J Appl Physiol 75:1897, 1993
36. Grau GE, Colford P: The influence of soluble receptors on cytokine measurement. J NIH Res 6:75, 1994
37. Keuter M, Dharmana E, Husein Gasem M, Van der VenJongekrijg J, Djokomoeljanto R, Dolmans WMV, Demacker P, Sauerwein R, Gallati H, Van der Meer JWM: Patterns of proinflammatory cytokines and inhibitors during typhoid fever. J Infect Dis 169:1306, 1994
38. Nualláin EMÓ, Puri P, Mealy K, Reen DJ: Induction of interleukin-1 receptor antagonist (IL-1ra) following surgery is associated with major trauma. Clin Immunol Immunopath 76:96, 1995
39. Drenth JPH, Van Deuren M, Van der Ven-Jongekrijg J, Schalkwijk CG, Van der Meer JWM. Cytokine activation during attacks of the hyperimmunoglobulinaemia D and periodic fever syndrome. Blood 85:3586, 1995
40. Granowitz EV, Santos AA, Poutsiaka DD, Cannon JG, Wilmore DW, Wolff SM, Dinarello CA: Production of interleukin-1-receptor antagonist during experimental endotoxaemia. Lancet 338:1423, 1991
41. Orencole SF, Fantuzzi G, Vannier E, Dinarello CA: Circulating levels of IL-1 soluble receptors in health and after endotoxin or IL-2 administration (Abstract). Cytokine 7:642, 1995
42. Van der Poll, De Waal Malefyt R, Coyles SM, Lowry SF: Antiinflammatory cytokine responses during clinical sepsis and experimental endotoxemia: Sequential measurements of plasma soluble interleukin(IL)-1 receptor type II, IL-10, and IL-13. J Infect Dis 175:118, 1997
43. Akahoshi T, Oppenheim JJ. Matsushima K: Induction of high-affinity interleukin 1 receptor on human peripheral blood lymphocytes by glucocorticoid hormones. J Exp Med 167:924, 1988
44. Fasano MB, Cousait S, Neal S, McCall CE: Increased expression of the interleukin-1 receptor on blood neutrophils of humans with the sepsis syndrome. J Clin Invest 88:1452, 1991
45. Takao T, Gulp SG, De Souza EB: Reciprocal modulation of interleukin-1β (IL-1β) and IL-1 receptors by lipopolysaccharide (endotoxin) treatment in the mouse brain-endocrine-immune axis. Endocrinology 132:1497, 1993
46. McCall CE, Grosso-Wilmoth M, LaRue K, Guzman RN, Cousart SL: Tolerance to endotoxin-induced expression of the interleukin-1β gene in blood neutrophils of humans with sepsis syndrome. J Clin Invest 91:853, 1993
47. Brandtzaeg P, Mollnes TE, Kierulf P: Complement activation and endotoxin levels in systemic meningococcal disease. J Infect Dis 160:58, 1989
48. Brandtzaeg P, Høgåsen K, Kierulf P, Mollnes TE: The excessive complement activation in fulminant meningococcal septicemia is predominantly caused by alternative pathway activation. J Infect Dis 173:647, 1996
49. Colotta F, Orlando S, Fadlon EJ, Sozzani S, Matteucci C, Mantovani A: Chemoattractants induce rapid release of the interleukin 1 type II decoy receptor in human polymorphonuclear cells. J Exp Med 181:2181, 1995
50. Brown EA, Dare HA, Marsh CB, Wewers MD: The combination of endotoxin and dexamethasone induces type II interleukin 1 receptor (IL-1r II) in monocytes: A comparison to interleukin 1β (IL-1β) and interleukin 1 receptor antagonist (IL-1ra). Cytokine 8:828, 1966